Relatively little is known about regulated glucagon secretion by human islet α cells compared to insulin secretion from  cells, despite conclusive evidence of dysfunction in both cell types in diabetes mellitus. Distinct insulin sequences in humans and mice permit in vivo studies of  cell regulation after human islet transplantation in immunocompromised mice, whereas identical glucagon sequences prevent analogous in vivo measures of glucagon output from human  cells. We used CRISPR/Cas9 genome editing to remove glucagon-encoding codons 2-29 in immunocompromised (NSG) mice, preserving production of other proglucagonderived hormones, like Glucagon-like-peptide 1. These NSG-Glucagon knockout (NSG-GKO) mice had phenotypes associated with glucagon signaling deficits, including hypoglycemia, hyperaminoacidemia, hypoinsulinemia, and islet α cell hyperplasia. NSG-GKO host metabolic and islet phenotypes reverted after human islet transplantation, and human islets retained regulated glucagon and insulin secretion. NSG-GKO mice provide an unprecedented resource to investigate unique, species-specific human α cell regulation in vivo. 3 Pancreatic islet α and β cells play an important role in maintaining euglycemia by secreting peptide hormones in response to glucose and other blood metabolites. In healthy β cells, hyperglycemia triggers insulin secretion, which promotes glucose uptake and glycogenesis or adipogenesis in 'insulin-target' organs. In contrast, α cell glucagon secretion, stimulated by hypoglycemia, amino acids, and autonomic nerve inputs, leads to glucose mobilization by promoting glycogenolysis and gluconeogenesis in 'glucagon-target' organs, like liver 1 . Impaired regulation or output of insulin and glucagon by human β cells and  cells underlies development and progression of diabetes mellitus. Thus, intensive efforts are focused on determining the physiological and pathological mechanisms governing human islet α cell and β cell function.
hormone products, including glucagon, oxyntomodulin, glicentin, glucagon-like peptide-1 (GLP-1) and glucagon-like peptide 2 (GLP-2) 11 . Differential proglucagon processing depends on coexpression of the prohormone convertase (PC) enzymes. In pancreatic islet α cells, PC2 enables cleavage of proglucagon into the mature 29 amino acid glucagon protein, which is entirely encoded by Gcg exon 3 12 . PC1/3 expression in enteroendocrine cells permits cleavage of proglucagon into other products, including GLP-1, a secreted incretin hormone that enhances postprandial insulin output by islet β cells [13] [14] [15] [16] [17] .
Glucagon production in mice has been eliminated by targeted mutation of the Gcg gene to generate the Gcg gfp allele; adult homozygous Gcg gfp/gfp mice appeared normoglycemic, but exhibited α cell hyperplasia and hypoinsulinemia 18 . In contrast, loss of glucagon signaling in mice with a glucagon receptor (Gcgr) deletion, by Gcgr antibody inactivation [19] [20] [21] [22] , or elimination of PC2 23, 24 results in more extensive metabolic phenotypes reflecting impaired gluconeogenesis and glycogenolysis, including elevated circulating amino acid levels and basal hypoglycemia. Therefore, the milder metabolic phenotypes of Gcg gfp/gfp mice 18 likely reflect the combined loss of mature glucagon and other products of proglucagon. Here we generated immunocompromised mice that solely lack mature glucagon coding sequences (NSG-GKO) and demonstrate the utility of NSG-GKO mice for analyzing human islet α cell function in vivo.
Results

Generation of NSG-GKO mice
To develop mice that permit transplantation of human islets and detection of human glucagon, we used CRISPR/Cas9 genome editing in NSG-derived oocytes to create an in-frame deletion of nucleotides from Gcg exon 3, which encode mature glucagon (Figures 1A and   S1A ). This strategy should preserve production of metabolic regulators derived from the proglucagon carboxy-terminus, including GLP-1. After generating candidate founder mice, genotype screening identified one NSG founder harboring an in-frame 93 base pair (bp) deletion of the 3' end of glucagon exon 3. This in-frame deletion includes the elimination of 84 nucleotides encoding amino acids 2-29 of mature glucagon (Figures 1A-B and S1A).
Subsequent breeding of heterozygous F1 mice produced viable, fertile homozygous NSG-GKO mice that were born at a rate of 22.1% (compared to 32.8% wild type, and 45.1% heterozygous; n= 122 mice). While three-week-old male and female NSG-GKO mice weighed significantly less than NSG control littermates, no difference in body weight was detected in adult mice at eight weeks of age (Figure S1C) . This transient reduction of body mass in NSG-KO mice likely reflects a combination of reduced circulating insulin levels in NSG-GKO mice (see below), and possibly unrecognized roles for glucagon in development [25] [26] [27] [28] . Thus, beginning at eight weeks of age, NSG-GKO mice of both sexes were characterized for phenotypes associated with glucagon signaling loss.
To validate elimination of mature glucagon, plasma glucagon levels were measured from ad libitum fed and fasted NSG-GKO and NSG control mice. Unlike control NSG mice, plasma glucagon was undetectable in NSG-GKO mice in both fed and fasted states ( Figure 1C) . By contrast, plasma GLP-1 levels and excursion following an oral glucose tolerance test were similar between NSG-GKO and NSG control littermates, despite the increased glucose tolerance seen in NSG-GKO mice (Figures 1D and S1D) . Consistent with this, antibodies that detect mature glucagon (GCG1-29) did not label islet α cells in NSG-GKO mice, whereas these cells were readily identified with an antibody that detects proglucagon ( Figure S1B) . Thus, our CRISPR-based strategy successfully eliminated glucagon production while preserving GLP-1 output in NSG-GKO mice. 6 To assess the possibility of measuring circulating glucagon from human islets in NSG-GKO mice, we transplanted human islets from previously-healthy donors under the renal capsule of NSG-GKO mice (NSG-GKO Tx mice) (Figure 2A) . Plasma glucagon was detectable in NSG-GKO Tx mice two weeks after transplantation and thereafter for at least fourteen weeks, at which point NSG-GKO Tx mice were sacrificed for tissue analysis. Four weeks after human islet transplantation, plasma glucagon levels in fasted NSG-GKO Tx and control NSG mice were remarkably similar, but circulating glucagon remained undetectable in sham-transplanted NSG-GKO mice (Figure 2B) .
Transplanted human islets retain regulated glucagon secretion in NSG-GKO mice
To assess dynamic regulation of glucagon secretion from human  cells in NSG-GKO Tx mice, we measured glucagon secretion in vivo after an intraperitoneal insulin challenge, which elicits transient hypoglycemia. Reduced blood glucose levels stimulate  cell glucagon secretion 1, 29 , and, as expected, acute hypoglycemia was accompanied by increased circulating glucagon levels in NSG controls (Figures 2C and S2 These results suggest human  cell mechanisms governing regulated glucagon secretion remained intact after transplantation. 7 Glucagon signaling is an essential regulator of hepatic amino acid metabolism, gluconeogenesis, and glycogenolysis 20, 30, 31 . Consistent with prior mouse models of impaired glucagon signaling from glucagon or glucagon receptor deficiency [20] [21] [22] , we observed increased total plasma amino acid levels in NSG-GKO mice compared to NSG control littermates ( Figure   3A ). Moreover, measures of individual amino acids revealed specific amino acids that showed a significant increase in NSG-GKO mice, including arginine, alanine, threonine, serine, leucine, and glycine (Figures 3B and S3) . To examine the impact of glucagon loss on gluconeogenesis and amino acid metabolism, hepatic gene expression of enzymes involved in gluconeogenesis (G6pc and Pepck) and amino acid metabolism (Tat, Oat, Nnmt, and Gls2) were measured by qPCR. Hepatic expression of G6pc, Tat, Oat, Nnmt, and Gls2 was significantly decreased in NSG-GKO mice compared to NSG controls ( Figure 3D ). To assess differences in glycogenolysis, liver glycogen levels were measured from fasted NSG-GKO and NSG control mice. We observed a trend of increased average hepatic glycogen levels in NSG-GKO mice compared to NSG control ( Figure 3C ). Together, these data suggest that, like in previous studies of glucagon signalling loss 20-22, 24, 38 , gluconeogenesis and amino acid metabolism are impaired in NSG-GKO mice.
Human islets establish a glucagon-signaling axis that corrects liver phenotypes in NSG-
GKO mice
To determine if human islet-derived glucagon was able to rescue phenotypes associated with glucagon loss in NSG-GKO host tissues, we examined NSG-GKO Tx mice for reversion of liver phenotypes. Fourteen weeks after human islet transplantation, we observed corrections of liver defects, including reduction of total and individual plasma amino acids ( Figures 3A-B and   S3 ), a reduction in liver glycogen levels ( Figure 3C) , and normalization of hepatic G6pc, Tat, Oat, and Gls2 expression ( Figure 3D ). Together, these findings suggest that glucagon secretion by human islet grafts durably reconstituted a physiological islet-liver signaling axis. 8 Impaired glucagon signaling in mice can evoke compensatory  cell proliferation and hyperplasia 19, 23, 24, 32 . Elevated circulating amino acids in mice lacking glucagon signaling were previously demonstrated to induce α cell proliferation and hyperplasia [20] [21] [22] through a mechanism involving the  cell amino acid transporter Slc38a5 20, 21 . As NSG-GKO mice exhibited hyperaminoacidemia, we next assessed islet  cell and  cell hyperplasia and proliferation in NSG-GKO islets. For  cell morphometry in NSG-GKO islets, we used a proglucagon-specific antibody that detected both wild type and internally-deleted GKO proglucagon (proglucagon), and antibodies to detect MafB 33 , an adult  cell-specific islet transcription factor in mice (Figures 4A-H) . In response to amino acids, mouse  cells proliferate and induce expression of Slc38a5 21, 22 , which is also expressed in mouse acinar cells 22, 34 . NSG-GKO mice showed an increase in  cell expression of Slc38a5 compared to islets from NSG control mice (Figures 4I-N) , consistent with these prior studies. Thus, like in prior models of glucagon deficiency, we observed adaptive  cell expansion, stimulated by hyperaminoacidemia and accompanied by Slc38a5 expression.
Glucagon secreted by human islet grafts corrects α cell hyperplasia in NSG-GKO mice
As human glucagon from islet grafts restored circulating amino acid levels in NSG-GKO mice (Figures 3A-B) , we next assessed the impact on host islet α cells in NSG-GKO Tx mice and controls. Morphometry revealed that host α cell mass 'normalized' in NSG-GKO Tx mice compared to NSG control mouse islets (Figures 4C-D) , and was accompanied by a reduction in the number of proglucagon + Ki67 + cells (Figures 4G-H) , and loss of Slc38a5 production in mouse α cells (Figures 4O-Q) . Thus, restoration of glucagon signaling by human islet grafts in NSG-GKO mice corrected adaptive pancreatic islet α cell expansion observed in NSG-GKO mice. 9 
Restoration of glucose and insulin regulation in transplanted NSG-GKO mice
Glucagon increases blood glucose levels by promoting hepatic glucose output and is also implicated in regulating normal insulin secretion [35] [36] [37] . Hence, mice lacking glucagon signaling are hypoinsulinemic 18 and hypoglycemic 19, 23, 38 . Consistent with these extant glucagon signaling mutant mouse models, NSG-GKO mice had chronically reduced blood glucose levels and lower ad libitum fed plasma insulin levels compared to NSG control mice ( Figures 5A-B and S4B-C). Thus, transplanted human islets improved glycemic and insulin control in NSG-GKO Tx mice.
To examine insulin and glucose regulation further in NSG-GKO mice after human islet transplantation, we performed an intraperitoneal glucose challenge. Compared to NSG controls, glucose clearance by NSG-GKO mice was faster ( Figure 5C ) and accompanied by an exaggerated (mouse) insulin excursion (Figure 5D ). Glucose and insulin excursions in NSG-GKO Tx mice more closely resembled that of NSG controls (Figures 5C-D) . Dynamic total circulating insulin levels in NSG-GKO Tx mice reflected a combination of mouse and human insulins (Figures 5D-E) . Notably, it appeared that human insulin release from transplanted islets was well-regulated during glucose challenge, leading to acute rise then clearance from the circulation (Figure 5E) . These data suggest that human islet-derived glucagon improved 10 glycemic and insulin regulation in NSG-GKO Tx mice, and thus highlight the role of glucagon in maintaining euglycemia and normal insulin secretion. 11 
Discussion
To address the absence of models to study regulated glucagon secretion from human islet α cells in vivo, here we used CRISPR/Cas9 to develop a glucagon-null immunocompromised mouse strain (NSG-GKO). Human islets engrafted durably in NSG-GKO mice and retained regulated glucagon and insulin secretion. Reconstituting glucagon signaling to target organs, like the pancreas and liver, rescued multiple phenotypes associated with glucagon deficiency, including deviations in circulating glucose, amino acid, and insulin levels. Prior reports of mice that lack glucagon signaling 18-23, 41, 42 revealed many phenotypes associated with loss of glucagon signaling in pancreatic islets and other organs -phenotypes that we also observed in NSG-GKO mice. However, NSG-GKO mice also have distinct properties not previously reported 18, 23, 42 , likely reflecting preserved production of 'nested' proglucagon-derived peptides like GRPP, GLP-1, and GLP-2, in addition to the superior receptivity of the NSG strain background to xenotransplantation 6, 7 . While our approach led to the unavoidable loss of the oxyntomodulin and glicentin peptide hormones (which incorporate amino acids 1-29 of GCG), this also creates opportunities to study the in vivo functions of these hormones in NSG-GKO mice.
Glucagon is a crucial intercellular and inter-organ regulator of pancreatic islet cells, liver, and other organs 43 . Our results suggest that the NSG-GKO model should be useful for investigating these cell-signaling interactions. This proposal is based upon the observed reversal of hyperaminoacidemia, α cell hyperplasia, and islet Slc38a5 production in NSG-GKO mice after human islet transplantation, indicating (re)-establishment of at least two homeostatic in vivo signaling axes mediated by human glucagon and circulating amino acids. The first signaling axis links transplanted human islets to the host liver, and the second links the liver to native pancreatic islets cells. Further studies are needed to assess how other established intercellular inputs governing islet cell function and activity, like signaling from autonomic neurons, adrenal 12 hormones, or afferents from the CNS 44 might be reconstituted in the NSG-GKO model. Intraislet signaling between  cells,  cells, δ cells, and other islet cells is known to regulate islet hormone secretion 45, 46 . Glucagon is a direct regulator of insulin secretion, while insulin inhibition of glucagon secretion is thought to be mediated through δ cell-derived somatostatin 35, 36, 47 . For example, we observed that restored circulating glucagon in NSG-GKO Tx mice curbed the excessive insulin secretion response to hyperglycemia seen in NSG-GKO mice, providing evidence that glucagon acts to restrain β cell post-prandial insulin secretion that may otherwise cause hypoglycemia. Thus, to the extent that regulated reciprocal interactions between human  cells and β cells are reconstituted and measurable in NSG-GKO mice, these mice could be useful for in vivo studies of these and other intra-islet signaling interactions. For instance, δ cell somatostatin is an inhibitor of glucagon secretion [47] [48] [49] in rodents, and glucagon stimulates somatostatin secretion in perfused canine pancreas 50, 51 The NSG-GKO mouse allows powerful new ways to study human islets. To evaluate the function of candidate type 2 diabetes mellitus risk genes identified by GWAS and discover human islet  cell regulators, we previously used loss-, and gain-of-function genetics in human pseudo-islets transplanted in NSG mice 4, 10 . This experimental logic, using NSG-GKO mice, can now be expanded to human α cells in islets from previously-healthy, pre-diabetic, or diabetic donors. Importantly, we can now examine how  cell enriched genes 3, 52 and genetic changes in diabetes mellitus 3, 53, 54 impact human  cell identity and function. Moreover, we envision that NSG-GKO mice transplanted with islets from human donors (or other species) will be useful for examining how pharmacological agents, or acquired environmental stressors, like starvation or diet-induced obesity, impact human α cells. Using NSG mice, we recently reported that 13 responses of transplanted human islet  cells to high fat diet challenge were distinct from those observed in (host) mouse  cells 9 . Additionally, NSG-GKO mice should be useful for assessing the function of transplanted islet-like cells produced from renewable sources like human stem cell lines [55] [56] [57] [58] [59] . Thus, NSG-GKO mice should be a useful resource for in vivo studies of human islets, islet replacement cells using genetics, small molecules, or modeling of acquired in vivo physiological or pathological risk states in diabetes mellitus. NSG-GKO Tx mice, n= 6). Mice were given an intraperitoneal glucose tolerance test and monitored for blood glucose measures (C) and plasma mouse (D) and human (E) insulin levels (P values generated by repeated measures ANOVA, with Tukey's multiple comparisons test are listed in Table S3 ) (NSG mice, n= 3; NSG-GKO mice, n= 3; NSG-GKO Tx mice, n= 4). Human insulin excursion measured by human insulin-specific ELISA in the same IPGTT test as in panels C and D. Data are represented as mean of biological replicates ± SEM. * NSG vs. NSG- 18 GKO mice, + NSG-GKO vs. NSG-GKO Tx mice (C-D). + or * P ≤ 0.05, ++ or ** P ≤ 0.01, +++ or *** P ≤ 0.001. See also Table S3 and Figure S4 .
Figure Legends
Methods
Glucagon gene targeting in NSG mice
NSG-GKO mice were generated through the NIDDK Type 1 Diabetes Resource (TIDR) and the Jackson Laboratory. Two mouse glucagon Exon 3 guide RNAs (sgRNA 3569:
GAAGACAAACGCCACTCACA and sgRNA 3572: CAGACTCTTACCGGTTCCTCT) and the CRISPR/Cas9 plasmid were injected into NSG oocytes to generate founders. Out of 33 progeny, one male (termed 18-1) was confirmed by TOPO cloning and DNA sequencing to carry the desired in-frame deletion and bred to NSG females for germ line transmission. Verified primers, which produces a 715 bp wildtype product and 622 bp from the glucagon exon 3 deletion mutant ( Figure 1B) . Homozygous glucagon knockout mice were born at near Mendelian ratios. NSG-GKO mice were housed in a pathogen-free barrier facility at Stanford University Medical School, and were exposed to a normal 12-hour light cycle. Male and female mice (2-5 months old) were used for experiments along with age-and sex-matched control NSG mice.
Human islet procurement and transplantation
Deidentified human pancreatic islets were procured through the Integrated Islet Distribution Program and Alberta Diabetes Institute Islet Core. Five hundred human islet equivalents (IEQ) from previously healthy, nondiabetic organ donors (n=6) with less than 15hour cold ischemia time (Table 1) were used for transplantation under the kidney capsule of NSG-GKO mice as previously described 8, 10 . objective lens. For islet proliferation analysis and representative images presented in this manuscript, fluorescent micrographs were captured with a 40x objective lens. Images were processed in Image J for islet cell mass quantification and Image-Pro Plus for islet cell proliferation using previously described methods [60] [61] .
Glucose tolerance testing
Plasma hormones and amino acids assays
Liver glycogen content assessment
60 mg of tissue from the liver (left lateral lobe) was collected from mice fasted for 5 hours and flash frozen in liquid nitrogen. Liver samples were homogenized on ice in buffer containing protease cocktail inhibitor (Bimake) and quantified using a fluorometric glycogen assay kit according to manufacturer's instructions (Cayman Chemicals).
RNA isolation, cNDA synthesis, and quantitative PCR
90 mg of tissue from the liver (left lateral lobe) was collected from mice fasted for 5 hours. Then, total RNA was extracted using RNeasy Mini kit (Qiagen) and complementary DNA was synthesized using Maxima First Strand cDNA Synthesis kit (Thermo Fischer Scientific) following manufacturers' instructions. Quantitative PCR (qPCR) was performed using TaqMan 21 assays ( Supplementary Table 1 ) and reagents from Applied Biosystems with Actb used as an endogenous control.
Study approvals
All studies involving human islets were conducted in accordance with Stanford Unviersity 
Supplementary Tables
Gene Name Assay Number
Actb (Actin-B) Mm02619580_g1
G6p (Glucose-6-phosphate) Mm00839363_m1
Pepck (Phosphoenolpyruvate carboxykinase) Mm01247058_m1
Tat (Tyrosine Aminotransferase) Mm01244282_m1
Oat (Ornithine Aminotransferase) Mm00497544_m1
Nnmt (Nicotinamide N-methlytransferase) Mm00447994_m1
Gls2 (Glutaminase 2) Mm01164862_m1 Supplementary Table 1 . Taqman gene expression assay probes used in this study Supplementary Table 4 . P values for Figure S4 
